New sleep disorder drug ORX750 tested for Long-Term safety

NCT ID NCT07096674

Recruiting now Disease control Sponsor: Centessa Pharmaceuticals (UK) Limited Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is a long-term follow-up for people with narcolepsy or idiopathic hypersomnia who previously took the experimental drug ORX750. Researchers want to see if the drug remains safe and effective over time. About 90 participants will take ORX750 orally and be monitored for side effects and symptom control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ORX750 (oral drug)
What this could lead to: If successful, this could provide a long-term treatment option to help manage excessive daytime sleepiness and improve daily functioning for people with narcolepsy or idiopathic hypersomnia.
What could go wrong: This is an early-phase, open-label extension study with no placebo group, so results may not confirm effectiveness. Side effects or lack of sustained benefit could limit its use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Disorders of Excessive Somnolence idiopathic hypersomnia narcolepsy narcolepsy without cataplexy narcolepsy-cataplexy syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IDIOPATHIC HYPERSOMNIA NARCOLEPSY TYPE 1 NARCOLEPSY TYPE 2

Contacts and locations

Locations

Abington, Pennsylvania
RECRUITING

Abington, Pennsylvania, 19046, United States
Atlanta, Georgia
RECRUITING

Atlanta, Georgia, 30328, United States
Auburn, alabama
RECRUITING

Auburn, Alabama, 36832, United States
Austin, Texas
RECRUITING

Austin, Texas, 30328, United States
Bologna
RECRUITING

Bologna, BO, 40139, Italy
Cincinnati, Ohio
RECRUITING

Cincinnati, Ohio, 45245, United States
Denver, North Carolina
RECRUITING

Denver, North Carolina, 28037, United States
Dublin
RECRUITING

Dublin, Ohio, 43017, United States
El Paso, Texas
RECRUITING

El Paso, Texas, 79912, United States
Hendersen, Navada
RECRUITING

Henderson, Nevada, 89052, United States
Henderson, Nevada
RECRUITING

Henderson, Nevada, 89052, United States
Huntersville, North Carolina
RECRUITING

Huntersville, North Carolina, 28070, United States
Miami, Florida
RECRUITING

Miami, Florida, 33176, United States
Móstoles, Madrid
RECRUITING

Móstoles, Madrid, 28938, Spain
North Charleston, South Carolina
RECRUITING

North Charleston, South Carolina, 29406-9196, United States
Orlando, Florida
RECRUITING

Orlando, Florida, 32807, United States
Santa Ana, California
RECRUITING

Santa Ana, California, 92705, United States
Sterling Heights, Michigan
RECRUITING

Sterling Heights, Michigan, 48314, United States
Stockbridge, GA
RECRUITING

Atlanta, Georgia, 30281, United States
Toronto
RECRUITING

Toronto, Ontario, M5S 3A3, Canada
Verona
RECRUITING

Verona, VR, 37134, Italy
Willow Grove, Pennsylvania
RECRUITING

Willow Grove, Pennsylvania, 19090, United States
Winter Park, FL
RECRUITING

Winter Park, Florida, 32789, United States
Álava, Spain
RECRUITING

Álava, 01004, Spain

More trials for these conditions

Other studies related to the condition(s) this trial covers.